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ABSTRACT
Risk factors for COVID-19 patients with poorer outcomes 
include pre- existing conditions: obesity, type 2 diabetes 
mellitus, cardiovascular disease (CVD), heart failure, 
hypertension, low oxygen saturation capacity, cancer, 
elevated: ferritin, C reactive protein (CRP) and D- dimer. 
A common denominator, hyperinsulinaemia, provides 
a plausible mechanism of action, underlying CVD, 
hypertension and strokes, all conditions typified with 
thrombi. The underlying science provides a theoretical 
management algorithm for the frontline practitioners.
Vitamin D activation requires magnesium. 
Hyperinsulinaemia promotes: magnesium depletion 
via increased renal excretion, reduced intracellular 
levels, lowers vitamin D status via sequestration into 
adipocytes and hydroxylation activation inhibition. 
Hyperinsulinaemia mediates thrombi development 
via: fibrinolysis inhibition, anticoagulation production 
dysregulation, increasing reactive oxygen species, 
decreased antioxidant capacity via nicotinamide 
adenine dinucleotide depletion, haem oxidation and 
catabolism, producing carbon monoxide, increasing 
deep vein thrombosis risk and pulmonary emboli. 
Increased haem- synthesis demand upregulates carbon 
dioxide production, decreasing oxygen saturation 
capacity. Hyperinsulinaemia decreases cholesterol 
sulfurylation to cholesterol sulfate, as low vitamin 
D regulation due to magnesium depletion and/or 
vitamin D sequestration and/or diminished activation 
capacity decreases sulfotransferase enzyme SULT2B1b 
activity, consequently decreasing plasma membrane 
negative charge between red blood cells, platelets and 
endothelial cells, thus increasing agglutination and 
thrombosis.
Patients with COVID-19 admitted with hyperglycaemia 
and/or hyperinsulinaemia should be placed on a 
restricted refined carbohydrate diet, with limited use of 
intravenous dextrose solutions. Degree/level of restriction 
is determined by serial testing of blood glucose, insulin 
and ketones. Supplemental magnesium, vitamin D and 
zinc should be administered. By implementing refined 
carbohydrate restriction, three primary risk factors, 
hyperinsulinaemia, hyperglycaemia and hypertension, that 
increase inflammation, coagulation and thrombosis risk 
are rapidly managed.
INTRODUCTION
Individuals most at risk of poorer outcomes 
from SARS- CoV-2 infection causing COVID-19 
include those ≥65 years of age and/or those 
with pre- existing conditions such as: obesity, 
type 2 diabetes mellitus (T2DM) or elevated 
D- dimer1 2 and black, Asian and minority 
ethnic (BAME) individuals.1 3 A common 
denominator of these presentations, hyperin-
sulinaemia, has an explanation by the under-
lying science that provides the theory for our 
proposed management algorithm for front-
line practitioners.
There is a clear correlation between 
increasing age and increasing prevalence of 
metabolic disease including hypertension, 
stroke, T2DM, CVD and cancer occurrences. 
Yet this correlation is not causation. Those 
conditions, traditionally known as ‘diseases 
of ageing’, are occurring at higher rates in 
younger population groups.2 4 Chronic hyper-
insulinaemia provides a plausible mecha-
nism of action underlying the increase in 
these morbidities.5 This mechanism may also 
help to explain why these individuals have 
poorer outcomes associated with SARS- CoV-2 
infections.
Hyperglycaemia increases secretion of 
proinflammatory cytokine interleukin 6 
(IL-6) and blood coagulation via increasing 
hepatic clotting factors. Conversely, hyperin-
sulinaemia disturbs fibrinolysis by elevating 
plasminogen activator inhibitor type 1 
(PAI-1).6 7 Increased thrombi/emboli have 
been detected in postmortem findings in 
COVID-19 cases.8–12 In fact, pulmonary 
thrombi may be the cause of oxygen desatu-
ration and acute respiratory distress in many 
COVID-19 cases. Thus, strategies that can 
reduce the risk of disseminated intravascular 
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coagulopathy may improve oxygenation and outcomes 
in COVID-19.13 14
UNDERLYING SCIENCE FOR RATIONALE OF PROPOSED 
CLINICAL MANAGEMENT
Hyperglycaemia increases haemoglobin glycation 
damage.15 16 A study published in Diabetes Research and 
Clinical Practice analysed 132 patients with COVID-19, 
classified into three groups based on haemoglobin A1c 
(HbA1c) levels; results found a significant linear nega-
tive correlation between haemoglobin oxygen satura-
tion (SaO2)and HbA1c, p=0.01.
16 Hyperinsulinaemia 
inhibits beta- oxidation and ketolysis, thereby ‘enforcing’ 
cellular ATP generation from glucose substrate.17 
Glucose oxidation consumes four nicotinamide adenine 
dinucleotide (NAD+) to produce two acetyl moieties, 
whereas beta- oxidation consumes two, ketolysis one 
and acetoacetate none (online supplemental appendix 
A); consequently, glucose oxidation depletes the NAD+ 
intracellular pool more than the other three substrates 
combined, thereby decreasing NAD+ availability for 
mitochondrial deacetylase sirtuin 3 (SIRT3) activity.18 19 
NAD+ dependent SIRT3 activates manganese superoxide 
dismutase 2 (MnSOD2) via acetylation of lysine residue 
68 (K68) and increases the production of NADPH via 
isocitrate dehydrogenase (IDH2) to drive the reduction 
of oxidised glutathione (GSSG) to reduced glutathione 
(GSH). Coupled with the glucose fuelling effect on the 
cellular redox system, insulin increases mitochondrial 
production of reactive oxygen species (ROS) via gener-
ation of ceramides.20 Hyperglycaemia and hyperinsuli-
naemia are the twin blades of dysregulated ROS produc-
tion and management (figure 1).
The haem part of haemoglobin is synthesised in mito-
chondria. As a result of increased haemoglobin glycation 
and intracellular haem oxidative damage, an upreg-
ulated demand for synthesis of new haem to keep up 
the replenishment of damaged haem ensues. This may 
contribute to respiration independent increased carbon 
dioxide levels, as extramitochondrial haem synthesis 
step 5, produces four carbon dioxide molecules via the 
decarboxylation of uroporphyrinogen III to copropor-
phyrinogen III, further taxing the external respiration 
system. In addition, step 7 of haem synthesis generates 
the production of three hydrogen peroxide (H2O2) ROS 
molecules. Thus, increased haem damage that would 
necessitate an increased upregulation in haem synthesis 
may place further burden on the intracellular redox 
Figure 1 Schematic representation of the role of hyperinsulinaemia in endothelial/vascular inflammation, red blood cell (RBC) 
and platelet coagulation, sequestration and/or inhibition of vitamin D activation and its downstream consequences, such 
as decreased cholesterol sulfate (Ch- S), heparan sulfate proteoglycans (HSPG) and cathelicidin synthesis. Carbon dioxide 
(CO2), carbon monoxide (CO), deep vein thrombosis (DVT), endothelial nitric oxide synthase (eNOS), reduced glutathione 
(GSH), oxidised glutathione (GSSG), haemoglobin A1c (HbA1c), haem- oxygenase (HO), manganese superoxide dismutase 2 
(MnSOD2), nicotinamide adenine dinucleotide (NAD+), plasma membrane (PM), plasminogen activator inhibitor type 1 (PAI-
1), pulmonary embolism (PE), reactive oxygen species (ROS), oxygen saturation (SpO2), sirtuin 3 (SIRT3) and type 2 diabetes 
mellitus (T2DM).
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system. To compound the problem, mitochondrial elec-
tron transport chain (ETC) complexes, complex II and 
III require haem b (protoheme IX). Hyperglycaemia and 
hyperinsulinaemia increased intracellular ROS produc-
tion coupled with diminished mitochondrial stress 
management capacity, increases mitochondrial oxidative 
phosphorylation (mt- OxPhos) haem oxidation, reducing 
mt- OxPhos capacity.21
The breakdown of damaged haem activates signals 
for the synthesis of new haem. Haem- oxygenase (HO) 
induces hepatic aminolevulinic acid synthase (ALAS1) 
(enzyme in the first step of haem synthesis) activity. 
Haem is catabolised/degraded by HO (gene Hmox1/
Hmox2), producing ferrous iron, biliverdin and carbon 
monoxide, resulting in increased plasma ferritin and bili-
rubin. These markers have been shown to be significantly 
elevated in COVID-19 patients with poorer outcomes.22
Increased haem breakdown by HO produces endog-
enous carbon monoxide, which has a higher binding 
affinity with haemoglobin compared with oxygen. This 
would result in a decreased oxygen saturation capacity. 
Deep vein thrombosis occurrence increases signifi-
cantly with elevated carbon monoxide concentrations, 
increasing the risk of pulmonary emboli (PE) and acute 
coronary syndrome.23 24 Hyperinsulinaemia drives the 
pathogenesis of obesity, CVD, T2DM, hypertension, 
increased haem oxidation, haem breakdown, endog-
enous carbon monoxide production and resultant 
increased thrombi risk. Furthermore, D- dimer found 
to be markedly elevated in patients with COVID-19 is a 
direct marker for fibrinolytic and coagulation activity.25 26 
Patients with COVID-19 who have a high risk of venous 
thromboembolisms suffer poorer outcomes.22 Measuring 
carboxyhaemoglobin (COHb or HbCO) to assess 
carbon monoxide levels in COVID-19 positive patients is 
warranted and may provide further insight.
Vitamin D status has garnered great interest and debate 
with regards to risk/prevention of infection and prognosis 
in those with COVID-19.1 27 28 Evidence supports the argu-
ment that good levels of vitamin D status lowers the risk of 
contracting a respiratory infectious pathogen,29 possibly 
due to vitamin D induced increases in airway surface 
liquid epithelial production of antimicrobial and immu-
nomodulatory host defence peptide, cathelicidin.30–32
In a retrospective study of 107 patients in Switzerland, 
results showed 25- hydroxycholecalciferol D- calcidiol 
(25OHD, inactive D3) levels were significantly lower in 
patients that had a positive PCR for SARS- CoV-2, median 
value 11.1 ng/mL versus COVID-19 negative patients, 
who had significantly higher 25OHD levels at 24.6 ng/
mL, p=0.004. This study indicates vitamin D’s role in 
association with risk of infection, as opposed to disease 
severity and/or mortality, supporting an antiviral role 
for vitamin D3.33 Furthermore, a study published in the 
Irish Medical Journal found increased rates of vitamin D3 
deficiency in lower latitude countries such as Spain and 
Italy, despite being typically sunnier. The authors attri-
bute this to fortification and supplementation practices 
in their more northern European neighbours, as well as 
darker skin pigmentation and sun avoidance in southern 
warmer climate inhabitants.34 Epidemic acute respira-
tory infections result from a lack of sunlight exposure- 
generated vitamin D during winter and early spring; this 
most likely includes viral respiratory infection COVID-
19.35 Cannell et al35 demonstrated that groups low in 
vitamin D levels, including: obese, elderly, hyperinsuli-
naemic, dark skin and those with chronic health condi-
tions, required 5000 IU of vitamin D each day in order to 
obtain 125 nmol/L (50 ng/mL) plasma levels of 25OHD 
that appears to be protective against viral respiratory 
infection and sequalae. Further investigations into the 
relationship between vitamin D levels, age and COVID-19 
outcomes would be valuable.
A 2017 meta- analysis of 25 randomised controlled trials 
(RCTs) published in The BMJ, studying 11 000 participants 
given vitamin D or placebo, concluded that vitamin D 
supplementation is safe and protects against acute respi-
ratory tract infections, where the greatest benefit was seen 
in those most deficient and benefits were also greatest in 
subjects taking vitamin D daily.36 The study highlighted 
that only four people who are deficient in vitamin D 
need to be treated to prevent one case of acute infection. 
Additionally, critical care research has demonstrated the 
efficacy and importance of vitamin D contribution to 
survival in intensive care unit (ICU) patients with acute 
respiratory distress syndrome.37 Vitamin D operates by 
several mechanisms that are critical in immune defence, 
those include: maintenance of tight junctions, promotes 
the production of antimicrobial peptides cathelicidin 
and defensins in airway epithelia and macrophages31 
and moderates the inflammatory response.38 The hotly 
debated question is: is a low vitamin D status a marker or 
maker of poor health?
A low vitamin D status is associated with hyperinsulinae-
mia’s pathologies (obesity, T2DM, CVD and metabolic 
cancers).39 Insulin mediates de novo lipogenesis and 
adipogenesis.40 Hyperinsulinaemia sequesters lipophilic 
vitamin D3 into adipocytes.41 Insulin stimulates bone 
resorption and calcium (Ca2+) and phosphate release. 
Elevated plasma Ca2+ and phosphate inhibits renal 
enzymatic 25OHD-1α-hydroxylation (CYP27B1) activa-
tion of inactive 25OHD- calcidiol to biologically active 
1,25(OH)2D- calcitriol.42 CYP27B1 is a mitochondrial 
cytochrome P450 hydroxylase situated on the matrix 
side of the inner mitochondrial membrane. CYP27B1 
function is dependent on OxPhos NADPH production 
and healthy robust mitochondrial electron transport 
machinery.
Hyperglycaemia and hyperinsulinaemia both increase 
mitochondrial ROS (mtROS) production while 
decreasing ROS management capacity via depletion of 
NAD+, resulting in diminished MnSOD2 and a decreased 
GSH:GSSG ratio.19 43–47 A decreased ability to hydrox-
ylate and thus activate 25OHD- calcidiol to its active 
form 1,25(OH)2D- calcitriol, due to poor ETC health 
and diminished NADPH generation, may complicate 
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research findings in plasma measurements that typically 
measure total 25OHD- calcidiol. Additionally, it does 
not take into account vitamin D binding protein bound 
25OHD- calcidiol. Furthermore, some hydroxylation of 
inactive to active vitamin D occurs intracellularly within 
other tissues and may be inhibited by excessive mitochon-
drial ROS and NAD+ glucose metabolism depletion. This 
aspect of vitamin D metabolism may not be picked up 
with blood plasma measurements, where plasma total 
inactive 25OHD is the typical form of measure.42 Inter-
estingly, in a year- long weight loss intervention study, 56 
obese (body mass index >30 kg/m2) participants were 
randomised to a very low carbohydrate ketogenic diet 
(VLCKD) or a standard hypocaloric Mediterranean 
diet (SHMD). Both groups had significant increases in 
their serum 25OHD- calcidiol status with weight loss, as 
measured by chemiluminescence. However, the VLCKD 
group had a greater significant increase relative to the 
SHMD, from 18.4 to 29.3 ng/mL, p<0.0001 versus 17.5 
to 21.3 ng/mL, p=0.067, as well as decreases in C reac-
tive protein.48 These results indicate the role of dietary 
macronutrient distribution on insulin secretion stimulus 
and its consequential effect on mitochondrial vitamin D 
hydroxylation activity and possible inflammation medi-
ated depletion (usage) of vitamin D.
Vitamin D may be created in the skin via exposure 
to ultraviolet B (UVB) radiation from sunlight and 
consumed in the diet. The action spectrum for vitamin 
D generation is UVB 280–320 nm. The best time of 
sun exposure for optimal vitamin D generation from 
sunlight, at minimal risk of cutaneous malignant mela-
noma, is noon.49 Other less investigated aspects of the 
role of vitamin D, sun exposure and blood coagulability 
may play a crucial role in the increased risk of poorer 
outcomes seen in COVID-19 high- risk individuals, whose 
risk factors are arguably markers of hyperinsulinaemia. 
Years of hyperinsulinaemia that would manifest overt 
pathologies such as obesity, CVD, hypertension and 
cancer would come with an already heavy- risk burden 
list, which includes: increased haemoglobin glycation 
damage, intracellular haem- oxidation with reduced 
antioxidative capacity, increased haem- oxygenase haem 
catabolism thus producing increased endogenous carbon 
monoxide production, leading to increased risk of DVT 
and subsequent PE and decreased mitochondrial vitamin 
D hydroxylase activation.
Sunlight exposure driven photo- catalyses has potential 
effects on other less investigated roles in human health. 
One is in aiding in production of cholesterol sulfate (Ch- 
S). The majority of Ch- S is synthesised in the epidermis 
and supplied to the bloodstream. Ch- S constitutes the 
majority of blood sterol sulfates, having an ionic negative 
charge that imparts its amphiphilic property, enabling 
water solubility and free movement through intracel-
lular cytoplasm and extracellular plasma. Red blood cells 
(RBCs) and platelets produce Ch- S that aids in main-
taining their extracellular side plasma membrane nega-
tive charge, thus preventing thrombi and agglutination via 
maintaining electrorepulsion- driven dispersion.50 Endo-
thelial cells also synthesise Ch- S; the enzyme endothelial 
nitric oxide synthase (eNOS) is traditionally thought to 
mediate synthesis of nitric oxide (NO); however, it has 
been established that when eNOS is membrane bound, 
it is no longer able to synthesise NO.51–54 Membrane- 
bound eNOS lacks association with intracellular calmod-
ulin binding; this results in a closed conformation of the 
heterodimer enzyme. The closed conformation of eNOS 
has the potential to simultaneously transfer two electrons 
versus the open conformation that transfers one elec-
tron. Extracellular exclusion zone water is sensitive to 
sunlight’s infrared 270 nm spectrum. At this frequency, 
sunlight exposure elevates electrons to a higher exci-
tation level, facilitating activation of the water involved 
in the oxidation of thiosulfate to sulfate, the first step 
in producing the sulfate required for Ch- S synthesis.55 56 
Impaired zinc utilisation and deficiency is associated with 
T2DM and CVD.57 The catalytic activity of eNOS is zinc 
dependent, a deficiency in zinc would result in inhibition 
of eNOS sulfate synthesis and inhibition of eNOS may 
result in increased clotting.58
Following eNOS sulfate synthesis, sulfotransferase 
enzyme SULT2B1b catalyses cholesterol sulfurylation, 
producing Ch- S. Activated vitamin 1,25(OH)2D- calcitriol 
induces SULT2B1b expression and activity.59 60 Thus, 
completing a circle, where hyperinsulinaemia decreases 
vitamin D bioavailability, hydroxylation activation and 
consequently decreasing SULT2B1b sulfurylation of 
sulfate to cholesterol, thereby decreasing the nega-
tive charge that aids in dispersion around RBCs, plate-
lets and endothelial cells, thus increasing agglutination 
and thrombosis. Furthermore, sunlight exposure eNOS 
sulfate production provides for increased sulfate 
availability for heparan sulfate proteoglycan (HSPG) 
synthesis; HSPGs are robust anticoagulants and buffer 
glycation damage.61 Ch- S is necessary for RBCs to be able 
to deform in order to travel through tight vascular spaces 
while allowing the trafficking of cholesterol between cells 
to HDL- A1. In addition, sulfate provides a non- haem 
method of oxygen delivery to oxidative phosphoryla-
tion dependent cells. Global ‘lockdown strategies’ may 
have inadvertently reduced incidental sun exposure and 
consequently lowered vitamin D and sulfate synthesis.
Hyperinsulinaemia increases mitochondrial ROS, with 
consequences that are far reaching. Healthy robust mito-
chondria regulate intracellular magnesium (Mg2+) pools 
and modulate Mg2+ concentrations between the cytosol 
and mitochondrial compartments.62 Hyperinsulinaemia 
causes increased renal excretion of magnesium, and 
insulin resistance (IR) reduces intracellular magnesium 
levels.63 An Mg2+ deficiency (MgD) may exist in absence 
of hypomagnesaemia.64 MgD has been implicated in 
perturbations of pancreatic beta- cell function, hyperin-
sulinaemia, IR and CVD due to its diverse and essential 
roles in an extensive list of cellular metabolic pathways, 
not least counting ATP transport, DNA repair capacity 
and cell viability. Mg2+ is required to transport vitamin D 
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around in the blood, and activation of vitamin D to its 
active form via hepatic and renal hydroxylation is Mg2+ 
dependent.65 Clinical manifestations of MgD include, but 
are not limited to, hyperinsulinaemia’s metabolic pathol-
ogies such as T2DM, osteoporosis, vitamin D metabolism 
disorders, CVD and hyperglycaemia.66 67 There is a strong 
relationship between MgD and increased oxidative stress. 
MgD drives decreased expression and activity of antioxi-
dant defence enzymes glutathione peroxidase, SOD and 
catalase and decreased production of glutathione, further 
taxing mitochondrial health and subsequent increased 
ROS production and consequent oxidative damage to 
proteins, membranes and haem.68 69 MgD increases the 
production of cytokines: IL-1β, IL-6, tumour necrosis 
factor α and PAI-1.64 70 Hyperinsulinaemia increases 
production of PAI-1, coupled with MgD- induced 
increased production of PAI-1 that inhibits fibrinolysis, 
together they compound coagulation risk. Lower serum 
magnesium is associated with increased thrombotic risk 
and slowed fibrinolysis.71–73 Moreover, in vivo experi-
ments have shown that magnesium has antithrombotic 
effects and reduces mortality in induced pulmonary 
thromboembolism.74
An individual whose system is in a chronic state 
of hyperinsulinaemia already has increased risk of 
thrombi/clots. CVD and strokes are typified by thrombi. 
Thus, the association with lower vitamin D may be both 
a marker and maker of poor health due to hyperinsu-
linaemia inducing low vitamin D status/availability, as 
a result of vitamin D sequestration into adipocytes and 
prevention of hydroxylation by mitochondrial ROS 
sensitive 1α−25OHD- hydroxylase. Even with supple-
mentation or adequate sun exposure, a mismatched 
low vitamin K2 status needed to move Ca2+ into bones 
would further result in increased plasma Ca2+ inhibition 
of vit D activation. Hyperinsulinaemia mediates thrombi 
development via multiple modalities, those include but 
are likely not limited to: (A) inhibition of fibrinolysis, 
(B) increased mtROS production with decreased antiox-
idant capacity, leading to further oxidation of haem, (C) 
increasing haem breakdown product carbon monoxide 
that increases thrombosis and decreases oxygen satura-
tion capacity, (D) increased demand for haem synthesis 
resulting in increased H2O2 and OxPhos independent 
CO2 production, again further burdening the external 
respiratory system for removal of CO2 and (E) decreased 
Ch- S production via sulfurylation by SULT2B1b sulfo-
transferase due to hyperinsulinaemia’s affect driving 
low activated vitamin D regulation on SULT2B1b, 
leading to increased RBC and platelet agglutination and 
thrombosis.
When systemic health is already on the edge due to 
hyperinsulinaemia, then additionally challenged with an 
extra stressor such as COVID-19, it may not be able to 
handle any more. Individuals already in an excess coagu-
lable state, one more straw added in SARS- CoV-2 may be 
the straw that breaks the camel’s back.
RATIONALE FOR CLINICAL MANAGEMENT HYPOTHESES
Given the above theories whereby hyperinsulinaemia 
aggravates the SARS- CoV-2 disease progress, lifestyle strat-
egies that have been shown to be effective for managing 
hyperinsulinaemia and/or type 2 diabetes should also 
theoretically attenuate SARS- CoV-2 disease progression. 
Glucose restriction should be a primary focus; this leads 
to a decreased need/requirement for endogenous and/
or exogenous insulin, thus targeting and managing two 
problems in one step.75 76 The importance of managing 
hyperglycaemia via its, largely dietary, upstream medi-
ator, rather than management of elevated plasma glucose 
once it has been elevated already, cannot be overem-
phasised. In an RCT conducted by the ACCORD group, 
10 251 patients with a mean age of 63 years and median 
HbA1c of 8.1% were randomised to one of two groups, 
one to target lowering their HbA1c to 6%, via receiving 
intensive therapy (insulin), and the other group to target 
an HbA1c of 7.0%–7.9% following standard therapy. The 
primary outcomes measured were non- fatal stroke, non- 
fatal myocardial infarction and CVD death. The inter-
vention group receiving intensive therapy (insulin) to 
normalise their HbA1c had higher mortality, to the extent 
that after 3.5 years, this intervention was stopped. Their 
HbA1c was successfully lowered via the intensive therapy; 
however, there was no reduction in major CVD events 
while there was an increase in deaths.15 Implementation 
in management of hyperglycaemia should be targeted 
at what causes blood glucose to raise, its upstream effec-
tors, the vast majority of which is from dietary sources. 
By restricting glucose (consideration to be given with 
regards to intravenous glucose), this subsequently lowers 
insulin secretion.75
Methods may include implementing a well- formulated 
ketogenic diet (WFKD), low carbohydrate healthy fat 
diet (LCHF), low glycaemic load (GL) diet and dietary 
carbohydrate restriction in as much a practicable way 
as possible approach. Choice in approach may vary for 
a myriad of reasons; while nutritional ketosis is demon-
strated to be safe, it is not necessarily the primary focus 
in this instance. Whereas lowering hyperglycaemia and 
hyperinsulinaemia are at the forefront of the pathophysi-
ological development of increasing risk factors for poorer 
outcomes in at risk individuals.
Implementing a method that helps get patients into 
a ‘fasting mimicking state’ using any of these fasting 
mimicking diets, which has a phenotype of healthy blood 
glucose (3.5–6.0 mmol/L), insulin (<200 pmol/L) and 
ketones (<7.0 mmol/L in healthy individuals, ketones 
at ≤3.0 mmol/L is a respectable concentration in meta-
bolically unhealthy patients),77–79 where there is no drive 
to calorie restrict. Again bearing in mind, during acute 
care settings, the focus is on lowering both glucose and 
insulin through carbohydrate restriction, whereas the 
focus is not on achieving any particular ketosis goal, 
aside from ensuring avoidance of ketoacidosis—ketones 
≥7.0 mmol/L78 and/or presence of ketones plus lowered 
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serum bicarbonate <15–18 mmol/L, with concomitant 
hyperglycaemia (glucose levels>13.8 mmol/L (250 mg/
dL))—the triad of diabetic ketoacidosis.80–82 Monitoring 
serum bicarbonate provides a sensitivity test for any meta-
bolic acidosis with presence of ketones. Ketoacidosis 
does not occur unless there are presence of ketones with 
hyperglycaemia and bicarbonate levels start trending 
downwards, indicating insulin insufficiency, as seen in 
patients with type 1 diabetes mellitus (T1DM) who do not 
produce enough, if any insulin to regulate ketogenesis 
with hyperglycaemia.
It is important to note, in the case of T2DM, if carbohy-
drates are ingested, blood glucose will elevate and ketones 
will lower or be absent due to insulin production in T2DM 
hyperinsulinaemic individuals, which inhibits ketogen-
esis. In the case of T1DM, if carbohydrates are ingested 
and insulin and/or oral hypoglycaemic medications are 
stopped, these patients may present with both ketosis/
ketoacidosis and hyperglycaemia. Although carbohydrate 
restriction will manage hyperglycaemia (and hyperinsu-
linaemia in people with T2D), it is never recommended 
to stop insulin in patients with T1D. However, carbohy-
drate restriction will likely require the reduction of basal 
insulin and/or the reduction/cessation of short/rapid 
acting insulin.
Focus in clinical management in patients with COVID-19 
in hospital is to aim to keep them out of progression into 
the ICU. Carbohydrate restriction, with a maximum of 90 
g of carbohydrate per 24 hours, LCHF and WFKD diets 
implemented in hospital and clinical settings have been 
shown to be safe and effective.79 83 In addition, parenteral 
and enteral glucose- restricted feeding have been shown 
to be safe and effective should these be required.76 84 
Furthermore, coupled with remotely monitored depre-
scribing of medications,83 both safety and efficacy have 
also been demonstrated in the home setting.79 Based 
on the current clinical data and plausible mechanisms 
of action that drive an increased risk of infection, the 
thrombosis risk factor and possible increased thrombi 
‘load’ in at risk individuals, it may be prudent for clini-
cians to advise stay- at- home at risk and COVID-19 positive 
patients to implement a carbohydrate restricted diet.
No clear reference range for insulin exists; current 
practice has been to use insulin concentrations relative 
to glucose as a proxy for determining IR, which does not 
account for hyperinsulinaemia. While patients with an 
HbA1c >40 mmol/L can be presumed to be hyperinsu-
linaemic by default, a healthy- appearing glucose concen-
tration may be due to perniciously elevated insulin levels 
(hyperinsulinaemia) regulating blood glucose levels 
leading to a false negative result.85 If triglycerides are 
elevated (>1.7 mmol/L), or the patient has other signs 
of metabolic syndrome, then there should be a higher 
suspicion of hyperinsulinaemia. Hyperinsulinaemia 
precedes hyperglycaemia by up to 24 years.86 Insulin 
regulates lipolysis, fatty acid oxidation and consequently 
ketogenesis17, and while insulin- dependent T1DM 
requires exogenous insulin to prevent ketoacidosis where 
plasma ketones exceed >25.0 mmol/L concurrent with 
hyperglycaemia,78 a state of hyperinsulinaemia prevents 
ketogenesis. In healthy people, the presence of ketones 
below 7.0 mmol/L (absent of hyperglycaemia) have been 
shown to be safe and even therapeutic.19 87 However, in 
metabolically unstable patients, especially when ketosis 
may need to be induced, reducing the upper refer-
ence interval to 3.0 mmol/L may be preferable, while 
ensuring close monitoring of and no trending down-
wards of serum bicarbonate. Triaging glucose, insulin 
and ketone body beta- hydroxybutyrate (BHB) concen-
trations provides a refined ability to ascertain a patient’s 
physiological insulin concentration, where presence of 
ketones 0.5–3.0 mmol/L, fasting glucose concentration 
≤5.6 mmol/L and insulin assay (if practical) results may 
provide the valuable information needed to determine 
the degree of carbohydrate restriction a patient requires. 
Presence of BHB even at 0.5 mmol/L with fasting glucose 
concentration ≤5.6 mmol/L is a proxy marker for insulin 
levels being inside of a range that is likely to be non- 
pathological for the patient77 and indicates physiological 
insulin homeostasis range.
Insulin has a 5–15 min pulsatile secretory pattern and 
an ultradian oscillatory rhythm.88 A single fasting blood 
sample may miss its peak; when possible, gold standard 
practice would be to take three samples, 5 min apart or to 
consider a 2- hour postprandial level, especially if fasting 
insulin levels are <180 pmol/L.85 In order to deter-
mine the degree of carbohydrate restriction and depre-
scribing of medications a patient may require, multiple 
blood measurements of glucose, insulin and BHB taken 
at regular time point intervals through the course of 
multiple days must be performed. This then enables the 
determination of an individual patient’s physiological 
insulin concentration while also addressing the hyperin-
sulinaemia and hyperglycaemia in the process. If insulin 
is unable to be measured, then a normal level of blood 
glucose (3.5–6.0 mmol/L) in combination with physio-
logically healthy levels of BHB (0.5–3.0 mmol/L) could 
be considered a proxy for good insulin control. Please 
note that this may not be accurate if taken within 2 hours 
of a meal.
HbA1c, blood glucose, insulin, BHB and bicarbonate 
should be measured on entrance into hospital or ICU. 
Elevated HbA1c (>40 mmol/mol, 5.8%) without acidosis 
(lower bicarbonate <18 mmol/L)80–82 is to be treated as 
hyperinsulinaemia. When necessary, results are to be 
used to determine the degree of carbohydrate restriction 
required for either enteral or parenteral management. 
Hourly blood sampling to determine (figure 2):
1. Blood glucose (with detailed record of meal and drink 
intakes).
2. Ketone BHB.
3. Insulin if feasible (ideally obtain an average from three 
samples taken over 15 min).
4. Depending on the initial and subsequent postprandial 
levels, this will inform how frequently measurements 
should be made.
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5. Blood glucose is expected to respond first to the car-
bohydrate restriction, depending on the degree of 
restriction, and the degree and duration of IR and hy-
perinsulinaemia, the insulin levels may take longer to 
lower.
6. If control appears to be underway, measurements may 
be tapered to every 2 hours, then 4 hours or four times 
per day, depending on the level of control seen.
7. If measured levels do not appear to be responding to 
the degree of carbohydrate restriction, then it may be 
necessary to increase the degree of restriction.
8. If glucose levels are going up, and there are concerns 
about any form of metabolic acidosis (including ke-
toacidosis), close serum bicarbonate monitoring is 
advised.
Close attention must be paid towards the need for 
deprescribing medications when implementing a very low 
carbohydrate WFKD. As determined via non- randomised 
interventional trials and clinical applications of very 
low carbohydrate diets in patients with type 2 diabetes, 
fast- acting insulin, sulfonylurea and megalitinide drugs 
are stopped immediately on induction of very low 
carbohydrate restriction in order to prevent sudden 
hypoglycaemic events. If not completely terminating 
prescribed basal insulin immediately, a reduction of 
dosage to between 50% and 80% is required.79 89 Hourly 
glucose readings enable close monitoring to prevent 
hypoglycaemia in absence of nutritional ketosis and keto- 
adaptation, where it has been shown considerably lower 
glucose values may be well tolerated in individuals who 
are in nutritional ketosis.90–92 Sodium–glucose cotrans-
porter-2 (SGLT2) inhibitors medication should also be 
discontinued on start of carbohydrate restriction in order 
to prevent euglycaemic- diabetic- ketoacidosis.77
Additional medications to take into account include:
 ► Gliptins or glitazones – tailored and titrated down on 
an individualised approach.
 ► Glucagon- like peptide-1 (GLP1) receptor agonists – 
may be continued.
 ► Metformin – continued if well tolerated, has been 
shown to improve insulin sensitisation and thus 
potentially decrease higher insulin requirements, 
along with enabling the lowering of glucose without a 
high risk of hypoglycaemia. If a risk of lactic acidosis 
presents, discontinue.
Addressing hypertension and antihypertensive medica-
tions: refined carbohydrate restriction leads to lowered 
endogenous and/or exogenous insulin requirements; 
this results in increased renal sodium secretion and 
diuresis resulting in hypotension. Vigilant and frequent 
monitoring of blood pressure to avoid hypotension is 
vital, with according adjustments to antihypertensive 
medications. Increased sodium intake and/or moni-
toring for hyponatraemia may likely be needed if patients 
Figure 2 Clinical management schematic. Beta- hydroxybutyrate (BHB), high- density lipoprotein (HDL), low carbohydrate 
healthy fat diet (LCHF), low glycaemic load diet (LG), sodium–glucose cotransporter 2 (SGLT2), well- formulated ketogenic diet 
(WFKD) and upper tolerable limit (UTL).
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experience headaches or light- headedness.79 It is also 
important to discontinue sodium restriction recommen-
dations when implementing carbohydrate restriction as 
low sodium diets have been shown to increase MgD and 
IR, thus potentiating hyperglycaemia.93 94
Metformin, diuretics and proton pump inhibitors (PPI) 
drugs have been shown to increase incidence of hypo-
magnesaemia and are commonly prescribed to patients 
with T2DM, a condition of hyperinsulinaemia. A reduc-
tion in gastric acidity production by PPI drugs decrease 
Mg2+ solubility, thus decreasing absorption potential 
in the gastrointestinal (GI) tract; metformin causes GI 
Mg2+ loss, while diuretics and hyperglycaemia decrease 
renal tubular reabsorption of Mg2+.95–97 Patients imple-
menting very low carbohydrate restriction, where compli-
ance was confirmed by presence of capillary BHB, in a 
remote setting non- randomised intervention with online 
medical supervision, were prescribed daily supplemen-
tation doses for vitamin D3 and Mg2+ at: 1000–2000 IU 
vitamin D3, 500 mg magnesium oxide or 200 mg magne-
sium chloride.79
Other safe and likely beneficial therapies include zinc 
supplementation (11 mg for men and 8 mg for women, 
with an upper tolerable limit of 40 mg regardless of sex)98 
and high- noon sensible sun exposure (sans sunscreen), 
especially given these therapies have been demonstrated 
to be safe. Given the rationale for the clinical manage-
ment of COVID-19, it would be potentially of benefit for 
clinicians to advise patients and at- risk individuals who 
are at home to implement these practices, as prevention 
and earlier management will be more efficacious.76 79 83 89
DISCUSSION
While it is not clear what concentration of insulin is ideal 
for an individual patient, in terms of functional concen-
trations that work in healthy physiological homeostasis as 
opposed to chronic elevated concentrations that function 
in pathological adaptive homeostasis, and drives inflam-
mation and pathological cellular outcomes; healthy 
glucose concentrations at the cost of hyperinsulinaemia 
comes at a heavy price. Approaches to achieve both 
healthy glucose regulation and minimal insulin secre-
tion where ‘very little does the job’ should be managed 
from a top- down approach, where large changes in blood 
glucose concentrations are primarily driven by dietary 
sources, resulting in the subsequent need for more 
insulin, consequently driving a higher baseline level 
of insulin. Logically restricting dietary carbohydrates 
results in less extreme oscillations in blood glucose levels 
and subsequent stimulus and need for insulin. Testing 
dynamic insulin responses to meals and/or controlled 
glucose loads need to become the normal practice, where 
the focus is not specifically on IR, which may be physio-
logical glucose sparing in the case for low carbohydrate 
adherent individuals but to establish if hyperinsulinaemia 
exists and further enable fine tuning of what degree of 
carbohydrate restriction is ideal on an individual bases.
Hyperinsulinaemia drives mtROS production and 
diminishes cellular antioxidative countermeasures; the 
effects may be subtle yet profound. Such as decreasing 
NADPH production leads to a lowered ability to acti-
vate inactive 25OHD- calcidiol to its biologically active 
form, which subsequently affects active 1,25(OH)2D- 
calcitriol- dependent processes such as sulfurylation 
activity required to synthesise Ch- S in order to prevent 
agglutination and thrombosis via providing the elec-
tronegative repulsion force around RBCs, platelets and 
endothelial cells. Furthermore, antioxidant GSH produc-
tion is dependent on NADPH. Hyperinsulinaemia affects 
vitamin D bioavailability as a result of sequestration into 
adipocytes. Vitamin D synthesis, availability and activa-
tion functions in decreasing risk of contracting respira-
tory infections and decreasing coagulation/thrombosis. 
Hyperinsulinaemia driven increased mtROS production 
taxes haem synthesis, resulting in less haem availability 
for haem dependent processes, such as maintaining 
a healthy ETC and for haemoglobin to carry oxygen, 
further driving hypoxia and decreased oxygen satura-
tion capacity. Hyperinsulinaemia and hyperglycaemia 
increases oxidised haem which increases haem catab-
olism, resulting in chronic increased CO production. 
Chronic elevated CO levels in turn decrease oxygen 
saturation capacity and increase risk of DVT leading to 
increased risk of PE, while long- term lowered oxygen 
saturation capacity consolidates hypoxia and further 
mtROS.
Implementing glucose restriction aids to resolve hyper-
insulinaemia and hyperglycaemia and their twin effects 
in poorer outcomes in patients at risk or with COVID-19. 
Chronic stimulus of insulin secretion results in hyperin-
sulinaemia and its downstream pathological sequelae. 
Glucose drives insulin secretion, excessive dietary high 
GL carbohydrates consumed frequently and chronically 
drives pathological development of hyperinsulinaemia. 
Clinical management should be focused on lowering 
carbohydrate consumption to manage both hyperinsuli-
naemia and hyperglycaemia, coupled with the lowering 
and describing of glucose management and antihyper-
tensive medications, such as fast- acting and basal insulin. 
A decrease in dietary carbohydrate and its subsequent 
effects on lowering insulin secretion leads to rapid 
changes in blood pressure, requiring vigilant monitoring 
with describing of antihypertensive drugs, as carbohy-
drate restriction and resultant decrease in insulin facili-
tates return of homeostatic regulation of blood pressure. 
Thus, through carbohydrate restriction, three primary 
factors—hyperinsulinaemia, hyperglycaemia and hyper-
tension—that increase inflammation, coagulation and 
thrombosis risk are rapidly managed.
LIMITATIONS
While on admission, blood glucose and/or insulin may 
reflect a high normal result, this may not be normal 
for that person. Fasting insulin does not always identify 
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hyperinsulinaemia, a first test for glucose and insulin can 
appear healthy, as glucose levels sit within the healthy 
reference range, and insulin not above values seen in 
non- diabetics. Providing a hypothetical example to 
demonstrate the point, without any clear reference range 
for fasting insulin, using a hypothetical fasting insulin 
reference range of 21–153 pmol/L (3.5–25.5 µU/mL), 
where 1 µU/mL = 6 pmol/L99: a patient’s first blood 
test results may show, glucose 5 mmol/L with insulin 
144 pmol/L (24 µU/mL), consequently this patient 
would not be considered hyperinsulinaemic and there-
fore not triaged to clinical management of carbohydrate 
restriction in order to decrease risk of coagulation and 
thrombosis complications of COVID-19. In this example, 
the patient may be maintaining a healthy glucose concen-
tration via a pernicious chronically higher than ideal 
insulin concentration for that individual. Whereas a true 
non- hyperinsulinaemia individual may also have a fasting 
blood glucose of 5 mmol/L with insulin 24 pmol/L (4 
µU/mL), where the maintenance of a healthy fasting 
glucose is not sustained by a higher basal insulin level 
but by maintaining a low carbohydrate consumption that 
maintains healthy glucose levels and does not frequently 
stimulate insulin secretion. In both instances, glucose and 
insulin appear healthy. The only way to know if someone 
is hyperinsulinaemic (excluding those who have overt 
hyperglycaemia and/or overtly elevated insulin levels) is 
by postprandial dynamic testing. In our example above, if 
both patients were reassessed 2 hours postprandially, the 
first patient’s glucose may have returned to 6.5 mmol/L, 
while the insulin may be elevated to >1000 pmol/L (166 
µU/mL), while the second patient is more likely to have 
a blood glucose of 5.3 mmol/L and an insulin concentra-
tion of 144 pmol/L (24 µU/mL). The limitation of the 
first readings taken may lead a clinician to think a patient 
is neither hyperglycaemic nor hyperinsulinaemic, if they 
only go by the first test and do not perform multiple tests 
for the first days of admission. Postprandial dynamic 
testing is required to truly ascertain hyperinsulinaemia, 
therefore clinicians need to extrapolate backwards after 
the treatment of carbohydrate restriction to subsequently 
ascertain whether insulin was chronically elevated in 
that patient and to determine what is a healthy insulin 
concentration that is specific for individual patients.
It must also be emphasised that our proposed manage-
ment strategy is theoretical based on biochemical princi-
ples and practical strategies from dietary control of type 
2 diabetes. SARS- CoV-2 has placed unprecedented strain 
on many nation’s health systems but has also highlighted 
that metabolic health is key to good immunological 
health. A well- formulated dietary strategy that restricts 
carbohydrates should be inexpensive to implement, 
complementary to current treatment strategies and can be 
considered as part of home- based treatments. Although 
we may be overcautious with monitoring frequency, addi-
tional monitoring is required but may be dependent on 
the patient’s health status; experienced practitioners will 
be able to refine our recommendations.
CONCLUSION
Based on the underlying science, patients with COVID-19 
admitted with hyperglycaemia and/or hyperinsulinaemia 
should be theoretically triaged to a restricted carbohydrate 
management algorithm either enteral or parenteral. The 
degree of restriction and the level to be determined by 
serial testing of blood glucose, insulin and ketones. Intra-
venous solutions containing dextrose should be limited 
where possible. Additionally, supplemental vitamin D, 
magnesium and zinc should be administered.
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